Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) saw unusually-strong trading volume on Friday . Approximately 659,897 shares changed hands during trading, an increase of 141% from the previous session’s volume of 273,430 shares.The stock last traded at $15.07 and had previously closed at $14.36.

A number of equities analysts recently commented on ADMS shares. JMP Securities started coverage on Adamas Pharmaceuticals in a research report on Friday, April 1st. They set an “outperform” rating and a $29.00 price objective on the stock. Mizuho lifted their price objective on Adamas Pharmaceuticals from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Thursday, April 28th. Cowen and Company reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Thursday, May 12th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 16th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $44.00 price objective on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. Adamas Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $32.00.

The firm’s 50 day moving average price is $15.69 and its 200 day moving average price is $16.11. The stock’s market capitalization is $326.57 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.11. Equities analysts predict that Adamas Pharmaceuticals Inc. will post ($3.09) EPS for the current fiscal year.

A hedge fund recently raised its stake in Adamas Pharmaceuticals stock. Russell Frank Co boosted its position in Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 119.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 83,773 shares of the specialty pharmaceutical company’s stock after buying an additional 45,652 shares during the period. Russell Frank Co owned approximately 0.45% of Adamas Pharmaceuticals worth $2,395,000 as of its most recent filing with the SEC.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.